Tumorad® patent granted in Europe
Spago Nanomedical AB (publ) announce today that the European Patent Office (EPO) has granted the company´s patent application comprising product protection for Tumorad®.
Tumorad® is based on nanoparticles loaded with a radioisotope and holds potential to become a new treatment of cancer. Earlier this year the patent was approved in the USA.
The patent, with the title “Nanostructures and applications thereof” (patent number 3122383) is valid until 2035.
The approval means that Spago Nanomedical holds product protection for Tumorad® in the two largest markets for radionuclide therapies, USA and Europe. Further approvals in other territories, inicluding Japan, are pending.